ATP‐Noncompetitive Inhibitors of CDK–Cyclin Complexes
- 5 January 2009
- journal article
- review article
- Published by Wiley in ChemMedChem
- Vol. 4 (1) , 19-24
Abstract
Progression through the cell division cycle is controlled by a family of cyclin‐dependent kinases (CDKs), the activity of which depends on their binding to regulatory partners (cyclins A–H). Deregulation of the activity of CDKs has been associated with the development of infectious, neurodegenerative, and proliferative diseases such as Alzheimer's, Parkinson's, or cancer. Most cancer cells contain mutations in the pathways that control the activity of CDKs. This observation led this kinase family to become a central target for the development of new drugs for cancer therapy. A range of structurally diverse molecules has been shown to inhibit the activity of CDKs through their activity as ATP antagonists. Nevertheless, the ATP binding sites on CDKs are highly conserved, limiting the kinase specificity of these inhibitors. Various genetic and crystallographic approaches have provided essential information about the mechanism of formation and activation of CDK–cyclin complexes, providing new ways to implement novel research strategies toward the discovery of new, more effective and selective drugs. Herein we review the progress made in the development of ATP‐noncompetitive CDK–cyclin inhibitors.Keywords
This publication has 53 references indexed in Scilit:
- CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseasesKidney International, 2008
- CDK inhibitors in cancer therapy: what is next?Trends in Pharmacological Sciences, 2008
- p27 Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant ChemotherapyJNCI: Journal of the National Cancer Institute, 2006
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood, 2006
- Selectivity and potency of cyclin-dependent kinase inhibitorsThe AAPS Journal, 2006
- Genetic Evidence for Functional Dependency of p18Ink4c on Cdk4Molecular and Cellular Biology, 2004
- Cdk-mediated phosphorylation of pRB regulates HDAC binding in vitroBiochemical and Biophysical Research Communications, 2004
- Highly potent p21WAF1‐derived peptide inhibitors of CDK‐mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin AChemical Biology & Drug Design, 2002
- Role of pRB dephosphorylation in cell cycle regulationFrontiers in Bioscience-Landmark, 2000
- Analysis of p16INK4aand Its Interaction with CDK4Biochemical and Biophysical Research Communications, 1996